{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T20:02:15Z","timestamp":1792612935078,"version":"4.5.0"},"reference-count":38,"publisher":"Impact Journals, LLC","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2022,1,26]]},"DOI":"10.18632\/oncotarget.28185","type":"journal-article","created":{"date-parts":[[2022,1,27]],"date-time":"2022-01-27T13:55:25Z","timestamp":1643291725000},"page":"224-236","source":"Crossref","is-referenced-by-count":17,"title":["Impact of the glutathione synthesis pathway on sulfasalazine-treated endometrial cancer"],"prefix":"10.18632","volume":"13","author":[{"given":"Kanako","family":"Sendo","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology, Yamagata University Faculty of Medicine, Yamagata, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manabu","family":"Seino","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Yamagata University Faculty of Medicine, Yamagata, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuyoshi","family":"Ohta","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Yamagata University Faculty of Medicine, Yamagata, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Nagase","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Yamagata University Faculty of Medicine, Yamagata, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2022,1,26]]},"reference":[{"key":"1","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/S0140-6736(15)00130-0","article-title":"Endometrial cancer","volume":"38","author":"Darai","year":"2016","journal-title":"Lancet"},{"key":"2","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.ygyno.2013.09.008","article-title":"Post treatment surveillance of type II endometrial cancer patients","volume":"13","author":"Rimel","year":"2013","journal-title":"Gynecol Oncol"},{"key":"3","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1038\/sj.bjc.6603012","article-title":"Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers","volume":"9","author":"Chan","year":"2006","journal-title":"Br J Cancer"},{"key":"4","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1053\/beog.2000.0187","article-title":"Clear-cell and papillary serous cancer: treatment options","volume":"1","author":"Abeler","year":"2001","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"5","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.ygyno.2003.08.018","article-title":"Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases","volume":"9","author":"Lu","year":"2003","journal-title":"Gynecol Oncol"},{"key":"6","doi-asserted-by":"publisher","first-page":"4915","DOI":"10.2147\/CMAR.S179566","article-title":"Clinicopathological and survival analysis of uterine papillary serous carcinoma: a single institutional review of 106 cases","volume":"1","author":"Lang","year":"2018","journal-title":"Cancer Manag Res"},{"key":"7","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ygyno.2017.04.018","article-title":"Factors prognostic of survival in advanced-stage uterine serous carcinoma","volume":"14","author":"Westin","year":"2017","journal-title":"Gynecol Oncol"},{"key":"8","doi-asserted-by":"publisher","first-page":"F1000","DOI":"10.12688\/f1000research.17408.1","article-title":"Recent advances in endometrial cancer: a review of key clinical trials from 2015 to 2019","volume":"8","author":"Plaxe","year":"2019","journal-title":"F1000Res"},{"key":"9","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1038\/sj.bjc.6606071","article-title":"Role of multidrug resistance protein 2 (MRP2) in chemoresistance and clinical outcome in oesophageal squamous cell carcinoma","volume":"10","author":"Doki","year":"2011","journal-title":"Br J Cancer"},{"key":"10","doi-asserted-by":"publisher","first-page":"13207","DOI":"10.1038\/s41598-018-31069-2","article-title":"Tyrosine kinase receptor TIE-1 mediates platinum resistance by promoting nucleotide excision repair in ovarian cancer","volume":"8","author":"Yaegashi","year":"2018","journal-title":"Sci Rep"},{"key":"11","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.3390\/ijms19071882","article-title":"Glutathione in Ovarian Cancer: A Double-Edged Sword","volume":"1","author":"Serpa","year":"2018","journal-title":"Int J Mol Sci"},{"key":"12","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s13048-015-0140-8","article-title":"A metabolomic approach to identifying platinum resistance in ovarian cancer","volume":"8","author":"Rattan","year":"2015","journal-title":"J Ovarian Res"},{"key":"13","doi-asserted-by":"publisher","first-page":"31985","DOI":"10.18632\/oncotarget.25868","article-title":"Metabolomic analysis of uterine serous carcinoma with acquired resistance to paclitaxel","volume":"9","author":"Nagase","year":"2018","journal-title":"Oncotarget"},{"key":"14","doi-asserted-by":"publisher","first-page":"e81162","DOI":"10.1371\/journal.pone.0081162","article-title":"Cisplatin induces a mitochondrial-ROS response that contributes to cytotoxicity depending on mitochondrial redox status and bioenergetic functions","volume":"8","author":"Doetsch","year":"2013","journal-title":"PLoS One"},{"key":"15","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1093\/jn\/134.3.489","article-title":"Glutathione metabolism and its implications for health","volume":"13","author":"Turner","year":"2004","journal-title":"J Nutr"},{"key":"16","unstructured":"The human protein atlas. https:\/\/www.proteinatlas.org\/."},{"key":"17","doi-asserted-by":"publisher","first-page":"e49683","DOI":"10.1371\/journal.pone.0049683","article-title":"Frequent epigenetic silencing of the folate-metabolising gene cystathionine-beta-synthase in gastrointestinal cancer","volume":"7","author":"Ying","year":"2012","journal-title":"PLoS One"},{"key":"18","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.3892\/or_00000373","article-title":"Expression of cystathionine beta-synthase is downregulated in hepatocellular carcinoma and associated with poor prognosis","volume":"2","author":"Kim","year":"2009","journal-title":"Oncol Rep"},{"key":"19","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.ccr.2011.01.038","article-title":"CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc(-) and thereby promotes tumor growth","volume":"1","author":"Ishikawa","year":"2011","journal-title":"Cancer Cell"},{"key":"20","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.1158\/1078-0432.CCR-13-2805","article-title":"Reduced expression of miRNA-27a modulates cisplatin resistance in bladder cancer by targeting the cystine\/glutamate exchanger SLC7A11","volume":"2","author":"Catto","year":"2014","journal-title":"Clin Cancer Res"},{"key":"21","doi-asserted-by":"publisher","first-page":"2801","DOI":"10.1111\/cas.13728","article-title":"High expression of CD44v9 and xCT in chemoresistant hepatocellular carcinoma: Potential targets by sulfasalazine","volume":"10","author":"Torimura","year":"2018","journal-title":"Cancer Sci"},{"key":"22","doi-asserted-by":"publisher","first-page":"11676","DOI":"10.1158\/0008-5472.CAN-05-2754","article-title":"Motexafin gadolinium and zinc induce oxidative stress responses and apoptosis in B-cell lymphoma lines","volume":"6","author":"Magda","year":"2005","journal-title":"Cancer Res"},{"key":"23","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.canlet.2015.07.031","article-title":"Xc- inhibitor sulfasalazine sensitizes colorectal cancer to cisplatin by a GSH-dependent mechanism","volume":"36","author":"Huang","year":"2015","journal-title":"Cancer Lett"},{"key":"24","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1158\/0008-5472.CAN-12-3609-T","article-title":"xCT inhibition depletes CD44v-expressing tumor cells that are resistant to EGFR-targeted therapy in head and neck squamous cell carcinoma","volume":"7","author":"Kawana","year":"2013","journal-title":"Cancer Res"},{"key":"25","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/cdd.2015.93","article-title":"Loss of cysteinyl-tRNA synthetase (CARS) induces the transsulfuration pathway and inhibits ferroptosis induced by cystine deprivation","volume":"2","author":"Stockwell","year":"2016","journal-title":"Cell Death Differ"},{"key":"26","doi-asserted-by":"publisher","first-page":"162363","DOI":"10.1155\/2010\/162363","article-title":"Molecular profiling of endometrial malignancies","volume":"201","author":"Yeh","year":"2010","journal-title":"Obstet Gynecol Int"},{"key":"27","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nature14344","article-title":"Ferroptosis as a p53-mediated activity during tumour suppression","volume":"52","author":"Gu","year":"2015","journal-title":"Nature"},{"key":"28","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.redox.2015.07.008","article-title":"Antioxidant responses and cellular adjustments to oxidative stress","volume":"6","author":"Lamas","year":"2015","journal-title":"Redox Biol"},{"key":"29","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.canlet.2011.07.024","article-title":"Disruption of xCT inhibits cell growth via the ROS\/autophagy pathway in hepatocellular carcinoma","volume":"31","author":"He","year":"2011","journal-title":"Cancer Lett"},{"key":"30","doi-asserted-by":"publisher","first-page":"307","DOI":"10.3892\/ol.2016.4571","article-title":"xCT expression modulates cisplatin resistance in Tca8113 tongue carcinoma cells","volume":"1","author":"DU","year":"2016","journal-title":"Oncol Lett"},{"key":"31","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/1476-4598-12-138","article-title":"Ets-1 regulates intracellular glutathione levels: key target for resistant ovarian cancer","volume":"1","author":"Singh","year":"2013","journal-title":"Mol Cancer"},{"key":"32","doi-asserted-by":"publisher","first-page":"972913","DOI":"10.1155\/2013\/972913","article-title":"Role of glutathione in cancer progression and chemoresistance","volume":"201","author":"Domenicotti","year":"2013","journal-title":"Oxid Med Cell Longev"},{"key":"33","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/bjc.1987.148","article-title":"Depletion of tumour versus normal tissue glutathione by buthionine sulfoximine","volume":"5","author":"Siemann","year":"1987","journal-title":"Br J Cancer"},{"key":"34","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1200\/JCO.1994.12.1.194","article-title":"Phase I clinical trial of intravenous L-buthionine sulfoximine and melphalan: an attempt at modulation of glutathione","volume":"1","author":"Spriggs","year":"1994","journal-title":"J Clin Oncol"},{"key":"35","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.neuint.2010.01.004","article-title":"Glutathione depletion causes a JNK and p38MAPK-mediated increase in expression of cystathionine-gamma-lyase and upregulation of the transsulfuration pathway in C6 glioma cells","volume":"5","author":"McBean","year":"2010","journal-title":"Neurochem Int"},{"key":"36","doi-asserted-by":"publisher","first-page":"5405","DOI":"10.3892\/ol.2018.8066","article-title":"Metabolic networks in ferroptosis","volume":"1","author":"Shi","year":"2018","journal-title":"Oncol Lett"},{"key":"37","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1186\/1471-2407-9-372","article-title":"Early termination of ISRCTN45828668, a phase 1\/2 prospective, randomized study of sulfasalazine for the treatment of progressing malignant gliomas in adults","volume":"9","author":"Bours","year":"2009","journal-title":"BMC Cancer"},{"key":"38","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1111\/cas.13309","article-title":"Phase I study of salazosulfapyridine in combination with cisplatin and pemetrexed for advanced non-small-cell lung cancer","volume":"10","author":"Ozeki","year":"2017","journal-title":"Cancer Sci"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.28185","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,27]],"date-time":"2022-01-27T13:55:28Z","timestamp":1643291728000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.28185"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,26]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1,26]]}},"alternative-id":["28185"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.28185","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,26]]}}}